Fig. 2From: Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trialPatient disposition chart showing study participation. Of randomized patients, 214 (99.1%) were included in the full analysis and safety analysis sets. a Data for the primary endpoint were missing (n = 1). AE adverse eventBack to article page